DE602004026333D1 - NEUE KRISTALLINE FORMEN VON ä2-Ä1-(3,5-BISTRIFLUORMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-Ä1,2,3ÜÜTRIAZOL-4-YLÜ-PYRIDIN-3-YLü-(2-CHLORPHENYL)METHANON - Google Patents
NEUE KRISTALLINE FORMEN VON ä2-Ä1-(3,5-BISTRIFLUORMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-Ä1,2,3ÜÜTRIAZOL-4-YLÜ-PYRIDIN-3-YLü-(2-CHLORPHENYL)METHANONInfo
- Publication number
- DE602004026333D1 DE602004026333D1 DE602004026333T DE602004026333T DE602004026333D1 DE 602004026333 D1 DE602004026333 D1 DE 602004026333D1 DE 602004026333 T DE602004026333 T DE 602004026333T DE 602004026333 T DE602004026333 T DE 602004026333T DE 602004026333 D1 DE602004026333 D1 DE 602004026333D1
- Authority
- DE
- Germany
- Prior art keywords
- ylü
- utriazol
- bistrifluoromethylbenzyl
- ylu
- methanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51430003P | 2003-10-24 | 2003-10-24 | |
| PCT/US2004/030914 WO2005042515A1 (en) | 2003-10-24 | 2004-10-12 | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004026333D1 true DE602004026333D1 (de) | 2010-05-12 |
Family
ID=34549327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004026333T Expired - Lifetime DE602004026333D1 (de) | 2003-10-24 | 2004-10-12 | NEUE KRISTALLINE FORMEN VON ä2-Ä1-(3,5-BISTRIFLUORMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-Ä1,2,3ÜÜTRIAZOL-4-YLÜ-PYRIDIN-3-YLü-(2-CHLORPHENYL)METHANON |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7381826B2 (https=) |
| JP (1) | JP4959336B2 (https=) |
| KR (1) | KR100848407B1 (https=) |
| CN (1) | CN1863791B (https=) |
| AR (1) | AR046131A1 (https=) |
| AT (1) | ATE462700T1 (https=) |
| AU (1) | AU2004285855B8 (https=) |
| BR (1) | BRPI0415010B8 (https=) |
| CA (1) | CA2542140C (https=) |
| CL (2) | CL2009001310A1 (https=) |
| CR (1) | CR8353A (https=) |
| DE (1) | DE602004026333D1 (https=) |
| DK (1) | DK1675846T3 (https=) |
| EA (1) | EA008881B1 (https=) |
| EC (1) | ECSP066517A (https=) |
| ES (1) | ES2340772T3 (https=) |
| HR (1) | HRP20100207T1 (https=) |
| IL (1) | IL174926A0 (https=) |
| MA (1) | MA28329A1 (https=) |
| MY (1) | MY157375A (https=) |
| NO (1) | NO335090B1 (https=) |
| NZ (2) | NZ580480A (https=) |
| PE (1) | PE20050481A1 (https=) |
| PT (1) | PT1675846E (https=) |
| TW (1) | TW200524906A (https=) |
| UA (1) | UA82901C2 (https=) |
| WO (1) | WO2005042515A1 (https=) |
| ZA (1) | ZA200603234B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101568523A (zh) * | 2006-12-20 | 2009-10-28 | 伊莱利利公司 | 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法 |
| WO2009075778A2 (en) * | 2007-12-06 | 2009-06-18 | The Regents Of The University Of California | Nonpeptidic inhibitors of cruzain |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| CA2978736C (en) | 2015-03-04 | 2023-11-07 | Vanda Pharmaceuticals Inc. | Dosing regimen of tradipitant |
| WO2017031215A1 (en) * | 2015-08-17 | 2017-02-23 | Eli Lilly And Company | Process development of a pyridine-containing nk-1 receptor antagonist |
| CA3073998A1 (en) | 2017-09-13 | 2019-03-21 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| KR20250140655A (ko) * | 2017-11-17 | 2025-09-25 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 위장 질환의 치료 방법 |
| CN112218636B (zh) * | 2018-06-08 | 2025-05-06 | 万达制药公司 | 使用川地匹坦进行治疗的方法 |
| KR102863233B1 (ko) | 2018-09-28 | 2025-09-22 | 반다 파마슈티칼즈, 인코퍼레이티드. | 멀미에서의 트라디피탄트의 용도 |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020117811A1 (en) | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| JP2023515167A (ja) | 2020-02-25 | 2023-04-12 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによるアトピー性皮膚炎の改善された治療 |
| WO2021195205A1 (en) | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| CN120641099A (zh) | 2022-12-21 | 2025-09-12 | 万达制药公司 | 使用曲地匹坦的治疗方法 |
| EP4599831A1 (en) | 2024-02-09 | 2025-08-13 | Vanda Pharmaceuticals Inc. | Treatment of gastroparesis with tradipitant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
| GB9505492D0 (en) * | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
| GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
| DE69736390T2 (de) * | 1996-10-07 | 2007-07-26 | Merck Sharp & Dohme Ltd., Hoddesdon | Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum |
| MXPA02001565A (es) * | 1999-08-13 | 2005-07-14 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas. |
| EP1228068A1 (en) * | 1999-10-29 | 2002-08-07 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
| US20020044971A1 (en) * | 2000-07-07 | 2002-04-18 | Amidon Gordon L. | Dissolution rate of poorly soluble drugs |
| KR100755577B1 (ko) * | 2002-04-26 | 2007-09-12 | 일라이 릴리 앤드 캄파니 | 타키키닌 수용체 길항제로서의 트리아졸 유도체 |
-
2004
- 2004-10-12 NZ NZ580480A patent/NZ580480A/en unknown
- 2004-10-12 HR HR20100207T patent/HRP20100207T1/hr unknown
- 2004-10-12 BR BRPI0415010A patent/BRPI0415010B8/pt not_active IP Right Cessation
- 2004-10-12 ES ES04793893T patent/ES2340772T3/es not_active Expired - Lifetime
- 2004-10-12 AT AT04793893T patent/ATE462700T1/de active
- 2004-10-12 JP JP2006536635A patent/JP4959336B2/ja not_active Expired - Lifetime
- 2004-10-12 NZ NZ545917A patent/NZ545917A/en unknown
- 2004-10-12 US US10/574,712 patent/US7381826B2/en not_active Expired - Lifetime
- 2004-10-12 PT PT04793893T patent/PT1675846E/pt unknown
- 2004-10-12 CA CA2542140A patent/CA2542140C/en not_active Expired - Lifetime
- 2004-10-12 CN CN2004800291393A patent/CN1863791B/zh not_active Expired - Lifetime
- 2004-10-12 WO PCT/US2004/030914 patent/WO2005042515A1/en not_active Ceased
- 2004-10-12 EA EA200600829A patent/EA008881B1/ru not_active IP Right Cessation
- 2004-10-12 DK DK04793893.1T patent/DK1675846T3/da active
- 2004-10-12 AU AU2004285855A patent/AU2004285855B8/en not_active Expired
- 2004-10-12 DE DE602004026333T patent/DE602004026333D1/de not_active Expired - Lifetime
- 2004-10-12 KR KR1020067007751A patent/KR100848407B1/ko not_active Expired - Lifetime
- 2004-10-20 PE PE2004001008A patent/PE20050481A1/es not_active Application Discontinuation
- 2004-10-20 AR ARP040103801A patent/AR046131A1/es not_active Application Discontinuation
- 2004-10-21 MY MYPI20044338A patent/MY157375A/en unknown
- 2004-10-22 TW TW093132097A patent/TW200524906A/zh unknown
- 2004-12-10 UA UAA200604473A patent/UA82901C2/uk unknown
-
2006
- 2006-04-11 IL IL174926A patent/IL174926A0/en unknown
- 2006-04-21 CR CR8353A patent/CR8353A/es not_active Application Discontinuation
- 2006-04-21 ZA ZA200603234A patent/ZA200603234B/en unknown
- 2006-04-21 EC EC2006006517A patent/ECSP066517A/es unknown
- 2006-05-22 MA MA29043A patent/MA28329A1/fr unknown
- 2006-05-24 NO NO20062371A patent/NO335090B1/no unknown
-
2009
- 2009-05-29 CL CL2009001310A patent/CL2009001310A1/es unknown
- 2009-05-29 CL CL2009001311A patent/CL2009001311A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004026333D1 (de) | NEUE KRISTALLINE FORMEN VON ä2-Ä1-(3,5-BISTRIFLUORMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-Ä1,2,3ÜÜTRIAZOL-4-YLÜ-PYRIDIN-3-YLü-(2-CHLORPHENYL)METHANON | |
| DE60233608D1 (de) | Phenylpiperidinderivate als Serotonin-Wiederaufnahmehemmer | |
| LTC1463716I2 (lt) | Pirolidino ir piperidino dariniai kaip NK1 antagonistai | |
| ATE421965T1 (de) | Polymorphe formen von rifaximin als antibiotica | |
| ATE312833T1 (de) | Piperidinverbindungen zur verwendung als antiallergika | |
| ATE404537T1 (de) | Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung | |
| ATE531369T1 (de) | Polymorphe formen von 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidin-2,6-dion | |
| EE200300007A (et) | Heterotsüklilised tetrahüdropüridino- või piperidinoderivaadid | |
| ATE292128T1 (de) | Piperidinderivate als neurokinin 1 antagonisten | |
| DE50105126D1 (de) | Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis | |
| DE60113563D1 (de) | Substituierte 2-phenylaminoimidazolin-phenyl-ketonderivate als ip-antagonisten | |
| DE50302202D1 (de) | Neue 2,5-disubstituierte pyrimidinderivate | |
| ATE450526T1 (de) | Als antagonisten von histamin h3 geeignete piperidinderivate | |
| NO20011436D0 (no) | 2,2,6,6-dietyl-dimetyl-1-alkoksy-piperidin-forbindelser og deres korresponderende 1-oksider | |
| ATE308543T1 (de) | Piperidinderivate | |
| ATE339405T1 (de) | Neue kristalline modifikation des anhydrates von boscalid | |
| ATE460407T1 (de) | Kristalline formen von duloxetin als freie base | |
| EP1809613A4 (en) | PROCESS FOR THE PREPARATION OF 2,6-DIARYLPIPERIDINE DERIVATIVES | |
| DE602004010385D1 (de) | 3,4-disubstituierte 1,2,3,4-tetrahydropyridinderivate | |
| ATE320418T1 (de) | Substituierte benzo(b)azepin-2-on-verbindungen als schmerzmittel | |
| DE50100358D1 (de) | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten | |
| DE60216310D1 (de) | Substituierte 4-phenyl-4-(1h-imidazol-2-yl)-piperidinderivate zur verringerung von ischämischer schädigung | |
| ATE299138T1 (de) | Mandelatsalze von substituierten tetrazyklischen tetrahydrofuranderivaten | |
| IS8007A (is) | 4-(2-fenýlsúlfanýl-fenýl)-1,2,3,6-tetrahýdrópýridín afleiður sem serótónín endurupptöku hindrar | |
| NO20025475L (no) | Nye benzotiofenderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |